Acadia Pharmaceuticals | ACAD - Ebit


Acadia Pharmaceuticals reported $35.76M in EBIT for its fiscal quarter ending in September of 2025.





Ebit Change Date
Acadia Pharmaceuticals USD 35.76M 3.38M Sep/2025
ALKERMES USD 89.08M 3.9M Sep/2025
Alnylam Pharmaceuticals USD 29.4M 59.36M Dec/2025
Biogen USD 659.6M 157M Sep/2025
BioMarin Pharmaceutical USD 198.39M 230.08M Dec/2025
Bristol-Myers Squibb USD 3.47B 567M Dec/2025
Cara Therapeutics USD -2.39M 3.16M Mar/2025
Corcept Therapeutics USD 10.22M 16.46M Sep/2025
Cytokinetics USD -166.76M 55.25M Sep/2025
Eisai JPY 20.03B 6.36B Dec/2025
Eli Lilly USD 8.99B 1.57B Dec/2025
Incyte USD 383.88M 47.44M Dec/2025
J&J USD 5.11B 2.3B Dec/2025
Moderna USD -857M 597M Dec/2025
Neurocrine Biosciences USD 227.9M 11.4M Dec/2025
Pfizer USD 4.65B 71M Dec/2025
Prothena USD -39.76M 12.25M Sep/2025
PTC Therapeutics USD -81.62M 85.11M Dec/2025
Sarepta Therapeutics USD -62.88M 178.46M Sep/2025
Ultragenyx Pharmaceutical USD -114M 56.89M Dec/2025
Vanda Pharmaceuticals USD -10.28M 721K Dec/2024
Vertex Pharmaceuticals USD 1.26B 24.5M Dec/2025